Oncopharmpod
Sacituzumab govitecan + pembrolizumab and ASCO GI '26
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:17:50
- Mas informaciones
Informações:
Sinopsis
We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.
